Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2008-05-13
2008-05-13
Tsang, Cecilia J. (Department: 1654)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C514S002600
Reexamination Certificate
active
07371543
ABSTRACT:
Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
REFERENCES:
patent: 4784950 (1988-11-01), Hagen et al.
patent: 4904584 (1990-02-01), Shaw
patent: 5041376 (1991-08-01), Gething et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5180583 (1993-01-01), Hedner
patent: 5225537 (1993-07-01), Foster
patent: 5258288 (1993-11-01), Wydro et al.
patent: 5288629 (1994-02-01), Berkner
patent: 5460950 (1995-10-01), Barr et al.
patent: 5504064 (1996-04-01), Morrisey et al.
patent: 5516640 (1996-05-01), Watanabe et al.
patent: 5580560 (1996-12-01), Nicolaisen et al.
patent: 5648254 (1997-07-01), Mulvihill et al.
patent: 5788965 (1998-08-01), Berkner et al.
patent: 5817788 (1998-10-01), Berkner et al.
patent: 5824634 (1998-10-01), Merchant
patent: 5824639 (1998-10-01), Berkner
patent: 5833982 (1998-11-01), Berkner et al.
patent: 5837843 (1998-11-01), Smirnov et al.
patent: 5847085 (1998-12-01), Esmon et al.
patent: 5861374 (1999-01-01), Berkner et al.
patent: 5891843 (1999-04-01), Turecek et al.
patent: 5965425 (1999-10-01), Barr et al.
patent: 5986079 (1999-11-01), Barr et al.
patent: 6013620 (2000-01-01), Turecek et al.
patent: 6017882 (2000-01-01), Nelsestuen
patent: 6100061 (2000-08-01), Reiter et al.
patent: 6423826 (2002-07-01), Nelsestuen et al.
patent: 6475725 (2002-11-01), Reiter et al.
patent: 6693075 (2004-02-01), Nelsestuen
patent: 6747003 (2004-06-01), Nelsestuen
patent: 6762286 (2004-07-01), Nelsestuen
patent: 6806063 (2004-10-01), Pedersen et al.
patent: 6903069 (2005-06-01), Pingel et al.
patent: 7026524 (2006-04-01), Persson et al.
patent: 2003/0100506 (2003-05-01), Nelsestuen
patent: 2003/0100740 (2003-05-01), Persson et al.
patent: 2003/0104978 (2003-06-01), Persson et al.
patent: 2003/0211094 (2003-11-01), Nelsestuen
patent: 2003/0211460 (2003-11-01), Nelsestuen
patent: 0 296 413 (1988-12-01), None
patent: 0 354 504 (1990-02-01), None
patent: 0 370 205 (1990-05-01), None
patent: 0 512 011 (1992-11-01), None
patent: WO88/10295 (1988-12-01), None
patent: WO91/11514 (1991-08-01), None
patent: WO92/15686 (1992-09-01), None
patent: WO94/27631 (1994-12-01), None
patent: WO96/00577 (1996-01-01), None
patent: WO98/32466 (1998-07-01), None
patent: WO98/35026 (1998-08-01), None
patent: WO99/03498 (1999-01-01), None
patent: WO99/03887 (1999-01-01), None
patent: WO99/20767 (1999-04-01), None
patent: WO99/66031 (1999-12-01), None
patent: WO 00/26230 (2000-05-01), None
patent: WO 00/26354 (2000-05-01), None
patent: WO 00/28065 (2000-05-01), None
patent: WO 00/54787 (2000-09-01), None
patent: WO 00/66753 (2000-11-01), None
patent: WO 01/83725 (2001-11-01), None
patent: WO 02/02764 (2002-01-01), None
patent: WO 02/03075 (2002-01-01), None
patent: WO 02/22776 (2002-03-01), None
patent: WO 02/38162 (2002-05-01), None
patent: WO 03/093465 (2003-11-01), None
patent: WO 2004/029091 (2004-04-01), None
patent: WO 2004/083361 (2004-09-01), None
Bharadwaj, D., et al., “Factor VII Central—A Novel Mutation in the Catalytic Domain that Reduces Tissue Factor Binding, Impairs Activation by Factor XA, and Abolishes Amidolytic and Coagulant Activity,”J. Biological Chemistry271(48):30685-30691 (1996).
Bjoern, S., et al., “Human Plasma and Recombinant Factor VII—Characterization ofO-Glycosylations at Serine Residues 52 and 60 and Effects of Site-Directed Mutagenesis of Serine 52 to Alanine,”J. Biological Chemistry266(17):11051-11057 (1991).
Chang, J-Y., et al., “Replacing the First Epidermal Growth Factor-like Domain of Factor IX with That of Factor VII Enhances Activity In Vitro and in Canine Hemophilia B,”J. Clin. Invest. 100(4):886-892 (1997).
Chang, Y-J., et al., “Engineered Recombinant Factor VII Q217Variants with Altered Inhibitor Specificities,”Biochemistry38:10940-10948 (1999).
Kemball-Cook, G., et al., “Coagulation Factor VII Gln100→Arg—Amino Acid Substitution at the Epidermal Growth Factor 2-Protease Domain Interface Results in Severely Reduced Tissue Factor Binding and Procoagulant Function,”J. Biological Chemistry273(14):8516-8521 (1998).
Dickinson, C.D., et al., “Active Site Modification of Factor VIIa Affects Interactions of the Protease Domain with Tissue Factor,”J. Biological Chemistry272(32):19875-19879 (1997).
Dickinson, C.D., et al., “Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa,”Proc. Natl. Acad. Sci. USA93:14379-14384 (1996).
Huang, Q., et al., “Substrate Recognition by Tissue Factor-Factor VIIa—Evidence for Interaction of Residues Lys165and Lys166of Tissue Factor with the 4-Carboxyglutamate-Rich Domain of Factor X,”J. Biological Chemistry271(36):21752-21757 (1996).
Iino, M., et al., “Functional Consequences of Mutations in Ser-52 and Ser-60 in Human Blood Coagulation Factor VII,”Archives of Biochemistry and Biophysics352(2):182-192 (1998).
Jin, J., et al., “Factor VIIa's First Epidermal Growth Factor-like Domain's Role in Catalytic Activity,”Biochemistry38:1185-1192 (1999).
Kelly, C.R., et al., “Ca2+Binding to the First Epidermal Growth Factor Module of Coagulation Factor VIIa Is Important for Cofactor Interaction and Proteolytic Function,”J. Biological Chemistry272(28):17467-17472 (1997).
Leonard, B.J.N., et al., “Activation and Active Site Occupation Alter Conformation in the Region of the First Epidermal Growth Factor-like Domain of Human Factor VII,”J. Biological Chemistry275(45):34894-34900 (2000).
Persson, E., “Characterization of the interaction between the light chain of factor VIIa and tissue factor,”FEBS Letters413:359-363 (1997).
Persson, E., et al., “Site-directed mutagenesis but not γ-carboxylation of Glu-35 in factor VIIa affects the association with tissue factor,”FEBS Letters385:241-243 (1996).
Persson, E., et al., “Ca2+Binding to the First Epidermal Growth Factor-like Domain of Factor VIIa Increases Amidolytic Activity and Tissue Factor Affinity,”J. Biological Chemistry272(32):19919-19924 (1997).
Petersen, L.C., et al., “Binding of Zn2+to a Ca2+loop allosterically attenuates the activity of factor VIIa and reduces its affinity for tissue factor,”Protein Science9:859-866 (2000).
Petrovan, R.J., et al., “Role of Residue Phe225in the Cofactor-Mediated, Allosteric Regulation of the Serine Protease Coagulation Factor VIIa,”Biochemistry39:14457-14463 (2000).
Ruf, W., et al., “Importance of Factor VIIa Gla-Domain Residue Arg-36 for Recognition of the Macromolecular Substrate Factor X Gla-Domain,”Biochemistry38:1957-1966 (1999).
Shah, A.M., et al., “Manipulation of the membrane binding site of vitamin K-dependent proteins: Enhanced biological function of human factor VII,”Proc. Natl. Acad. Sci. USA95:4229-4234 (1998).
Shobe, J., et al., “Macromolecular Substrate Affinity for the Tissue Factor-Factor VIIa Complex is Independent of Scissile Bond Docking,”J. Biological Chemistry274(34):24171-24175 (1999).
Shobe, J., et al., “Regulation of the Catalytic Function of Coagulation Factor VIIa by a Conformational Linkage of Surface Residue Glu 154 to the Active Site,”Biochemistry38:2745-2751 (1999).
Cheung, Wing-Fai et al., “Localization Of An E0pitope Of A Calcium-Dependent Monoclonal Antibody To The N-Terminal Region Of The GLA Domain Of Human Factor VII”,Thrombosis Research, (1995), 79(2): 199-206.
Dickinson, Craig D. et al., “Influence of Cofactor Binding and Active Site Occupancy on the Conformation of the Macromolecular Substrate Exosite Of Factor VIIa”,J. Mol. Bio.(1998) 277:959-971.
Jin, Jianping et al., “Four Loops of the Catalytic Domain of Factor VIIa Mediate the Effect of the First EGF-like
Andersen Kim Vilbour
Bornaes Claus
Pedersen Anders Hjelholt
Maxygen Holdings Ltd.
Petithory Joanne R.
Powers Margaret A.
Teller Roy
Tsang Cecilia J.
LandOfFree
Factor VII or VIIa-like molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Factor VII or VIIa-like molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Factor VII or VIIa-like molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2783162